SCHEMBL4103172

SCHEMBL4103172

O=C(O)O[C@@H]1[C@@H](O)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O[C@H](CO)[C@H]1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LGALS8 O00214 4/20 0.52
▸ IGF2R P11717 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ FGF1 P05230 1/20 0.46
▸ FGF2 P09038 1/20 0.46
▸ VEGFA P15692 1/20 0.46
▸ HPSE Q9Y251 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ SELE P16581 1/20 0.44
▸ LGALS3 P17931 1/20 0.43
▸ LGALS4 P56470 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CD209 Q9NNX6 1/20 0.43
▸ GJA1 P17302 1/20 0.42
▸ GJB2 P29033 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1984503 0.86 LGALS8 (0.52) LGALS8IGF2RMEN1KMT2AFGF1
SCHEMBL15518255 0.86 LGALS8 (0.56) LGALS8IGF2RMEN1KMT2AFGF1
SCHEMBL1816454 0.84 LGALS8 (0.49) LGALS8IGF2RFGF1FGF2VEGFA
SCHEMBL4636640 0.84 LGALS8 (0.53) LGALS8IGF2RMEN1KMT2AFGF1
SCHEMBL4410620 0.83 MEN1 (0.58) LGALS8IGF2RMEN1KMT2AFGF1
SCHEMBL9684872 0.83 L3MBTL1 (0.47) LGALS8IGF2RPTPN1MAPT
SCHEMBL1234575 0.83 MEN1 (0.58) LGALS8IGF2RMEN1KMT2AFGF1
SCHEMBL11216298 0.83 L3MBTL1 (0.47) LGALS8IGF2RPTPN1MAPT
SCHEMBL4078803 0.83 MEN1 (0.58) LGALS8IGF2RMEN1KMT2AFGF1
SCHEMBL7567716 0.83 MEN1 (0.54) LGALS8MEN1KMT2AFGF1FGF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030194-A1 Process for Production of Glucuronic Acid and/or Glucuronolactone ENSUIKO SUGAR REFINING CO., LTD. (JP) 2009-01-29 — — US disclosed
CN-101171341-A Process for producing glucuronic acid and/or glucuronolactone ENSUIKO SUGAR REFINING (JP) 2008-04-30 — — CN disclosed
EP-1881078-A1 METHOD FOR PRODUCING GLUCURONIC ACID AND/OR GLUCURONOLACTONE Ensuiko Sugar Refining Company, Limited (JP) 2008-01-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030194-A1 Process for Production of Glucuronic Acid and/or Glucuronolactone UGGT1, GUSB, UGDH LGALS8 514/4885IGF2R 535/4885MEN1 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback